Britta Majchrzak-Stiller
5PUBLICATIONS
7CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Jul 27, 2024
Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetionamide) and Gemcitabine.Marie Buchholz, Britta Majchrzak-Stiller, Ilka Peters
|Oct 28, 2023
In Vitro Experiments on the Effects of GP-2250 on BRAF-Mutated Melanoma Cell Lines and Benign Melanocytes.Thilo Gambichler, Friederike Harnischfeger, Marina Skrygan
|Jun 30, 2023
GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway in pancreatic cancer cells.Britta Majchrzak-Stiller, Marie Buchholz, Ilka Peters
|Jul 09, 2022
Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma-A 3-D In Vitro Study.Claudia Baron, Marie Buchholz, Britta Majchrzak-Stiller
|Jun 10, 2022
New Therapy Options for Neuroendocrine Carcinoma of the Pancreas-The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo.Marie Buchholz, Johanna Strotmann, Britta Majchrzak-Stiller
Pageof 1
